

BIBLIOGRAPHY

Atiyya AW, Moldovan S, Adrian TE, Coy D, Walsh J, Brunnicardi FC 1997. Intra-islet somatostatin inhibits insulin (via a subtype-2 somatostatin receptor) but not islet amyloid polypeptide secretion in the isolated perfused human pancreas. *J Gastrointest Surg* 1(3):251–256.

Baldelli R, Battista C, Leonetti F, Ghiggi MR, Ribaud MC, Paoloni A, D'Amico E, Ferretti E, Baratta R, Liuzzi A, Trischitta V, Tamburrano G. 2003. Glucose homeostasis in acromegaly: effects of long-acting somatostatin analogues treatment. *Clin Endocrinol. (Oxf)*. 59(4):492-499.

Ballian N, Brunnicardi FC, Wang XP. 2006. Somatostatin and its receptors in the development of the endocrine pancreas. *Pancreas*. 33(1): 1-12.

Banting, F. G., & Best, C. H., 1990. Pancreatic extracts. 1922. *J Lab Clin Med*. 115 (2): 254-272.

Bass RT, Buckwalter BL, Patel BP, Pausch MH, Price LA, Strnad J, Hadcock JR. 1996. Identification and characterization of novel somatostatin antagonists. *Mol Pharmacol*. 50(4):709-715.

Bates CM, Kegg H, Petrevski C, Grady S. 2003. Expression of somatostatin receptors 3, 4, and 5 in mouse kidney proximal tubules. *Kidney Int*. 63 (1):53-63.

Bauer W, Briner U, Doepfner W, Haller R, Huguenin R, Marbach P, Petcher TJ, Pless. 1982. SMS 201-995: a very potent and selective octapeptide analogue of somatostatin with prolonged action. *Life Sci*. 31(11):1133-1140.

Bell GI, Yasuda K, Kong H, et al. 1995. Molecular biology of somatostatin receptors. *Ciba Found Symp*. 190: 65-88.

Benali N, Ferjoux G, Puente E, Buscail L, Susini C. 2000. Somatostatin receptors. *Digestion*. 62 Suppl 1:27-32.

Benali N, Ferjoux G, Puente E, Buscail L, Susini C. 2000. Somatostatin receptors. *Digestion* 62 (suppl) 1:27-32.

Bevilacqua S, Bonadonna R, Buzzigoli G, Boni C, Ciociaro D, Maccari F, Giorico MA, Ferrannini E 1987. Acute elevation of free fatty acid levels leads to hepatic insulin resistance in obese subjects. *Metabolism* 36(5):502-506.

Bito H., Mori M., Sakanaka C., Takano T., Honda Z., Gotoh Y., Nishida E., Shimizu T., 1994. Functional coupling of SSTR4, a major hippocampal somatostatin receptor, to adenylate cyclase inhibition, arachidonate release and activation of the mitogen-activated protein kinase cascade, *J. Biol. Chem.* 269(17):12722-12730.

Boden G. 1996. Fatty acids and insulin resistance. *Diabetes Care*. 19(4): 394-395.

Boehm BO, Lang GK, Jehle PM, Feldman B, Lang GE. 2001. Octreotide reduces vitreous hemorrhage and loss of visual acuity risk in patients with high-risk proliferative diabetic retinopathy. *Horm Metab Res*. 33(5):300-306.

Bougneres PF, Artavia-Loria E, Ferre P, Chaussain JL, Job JC. 1985. Effects of hypopituitarism and growth hormone replacement therapy on the production and utilization of glucose in childhood. *J Clin Endocrinol Metab*. 61(6):1152-1157.

Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ 1994. Immunoneutralization of endogenous glucagon with monoclonal glucagons antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. *Diabetologia* 37(10):985-993.

Bratusch-Marrain PR, Smith D, DeFronzo RA. 1982. The effect of growth hormone on glucose metabolism and insulin secretion in man. *J Clin Endocrinol Metab.* 55(5):973-982.

Brunicardi FC, Atiya A, Moldovan S, Lee TC, Fagan SP, Kleinman RM, Adrian TE, Coy DH, Walsh JH, Fisher WE. 2003. Activation of somatostatin receptor subtype 2 inhibits insulin secretion in the isolated perfused human pancreas. *Pancreas.* 27(4):84-89.

Brunicardi FC, Kleinman R, Moldovan S, Nguyen TH, Watt PC, Walsh J, Gingerich R. 2001. Immunoneutralization of somatostatin, insulin, and glucagon causes alterations in islet cell secretion in the isolated perfused human pancreas. *Pancreas.* 23(3):302-308.

Brunicardi FC, Wen D, Bradley JC, Elahi D, Miller C, Hanks J. 2000. The effect of intraislet somatostatin immunoneutralization on insulin secretion in the isolated perfused rat pancreas. *Int J Surg Investig.* 1(5):381-388.

Bruno JF, Xu Y, Song J, Berelowitz M. 1993. Tissue distribution of somatostatin receptor subtype messenger ribonucleic acid in the rat. *Endocrinology.* 133(6):2561-2567.

Bruns C, Lewis I, Briner U, Meno-Tetang G, Weckbecker G. 2002. SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile. *Eur J Endocrinol.* 146(5):707-716.

Bruns C, Weckbecker G, Raulf F, Lubbert H, Hoyer D 1995. Characterization of somatostatin receptor subtypes. *Ciba Found Symp.* 190: 89-101; discussion 101-110.

Buscail L, Delesque N, Esteve JP, Saint-Laurent N, Prats H, Clerc P, Robberecht P, Bell GI, Liebow C, Schally AV. 1994. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. *Proc Natl Acad Sci U S A.* 91(6):2315-2319.

Cai RZ, Szoke B, Lu R, Fu D, Redding TW, Schally AV. 1986. Synthesis and biological activity of highly potent octapeptide analogs of somatostatin. *Proc Natl Acad Sci U S A*. 83(6):1896-1900.

Cejvan K, Coy DH, Efendic S 2003. Intra-islet somatostatin regulates glucagons release via type 2 somatostatin receptors in rats. *Diabetes*. 52(5):1176-1181.

Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM. 1998. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. *Science* 282(5389):737-740.

Cherrington AD, Williams PE, Shulman GI, Lacy WW 1981. Differential time course of glucagon's effect on glycogenolysis and gluconeogenesis in the conscious dog. *Diabetes*. 30(3):180-187.

Conlon JM, McCulloch AJ, Alberti KG. 1983. Circulating somatostatin concentrations in healthy and non-insulin-dependent (type II) diabetic subjects. *Diabetes*. 32(8):723-729.

Cordelier P., Esteve J.P., Bousquet C., Delesque N., Am O.C., Schally A.V., Vaysse N., Susini C., Buscail L., 1997. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5, *Proc. Natl. Acad. Sci. USA* 94(17): 9343-9348.

Cristiani R, Petrucci C, Dal Monte M, Bagnoli P. 2002. Somatostatin (SRIF) and SRIF receptors in the mouse retina. *Brain Res*. 936(1-2):1-14.

Da Silva Xavier G, Leclerc I, Salt IP, Doiron B, Hardie DG, Kahn A, Rutter GA. 2000. Role of AMP-activated protein kinase in the regulation by glucose of islet beta cell gene expression. *Proc Natl Acad Sci U S A*. 97(8):4023-4028.

Da Silva Xavier G, Leclerc I, Varadi A, Tsuboi T, Moule SK, Rutter GA. 2003. Role for AMP-activated protein kinase in glucose-stimulated insulin secretion and preproinsulin gene expression. *Biochem J.* 371(Pt 3):761-774.

Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontes G, Hani EH, Bataille D. 2004. Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line and isolated islets of Langerhans. *J Biol Chem.* 279(19):20345-20355.

Ding WQ, Dong M, Ninova D, Holicky EL, Stegall MD, Miller LJ. 2003. Forskolin suppresses insulin gene transcription in islet β -cells through a protein kinase A-independent pathway. *Cell Signal.* (1):27-35.

Dinneen S, Alzaid A, Turk D, Rizza R 1995. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. *Diabetologia.* 38(3): 337-343.

Drucker DJ, Philippe J, Mojsov S, Chick WL, Habener JF. 1987. Glucagon-like peptide-1 stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. *Proc Natl Acad Sci U S A* 84:3434–3438.

Elrick LJ, Docherty K. 2001. Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1. *Diabetes.* 50(10):2244-2252.

Fagan SP, Azizzadeh A, Moldovan S et al. 1998. Insulin secretion is inhibited by subtype five somatostatin receptor in the mouse. *Surgery.* 124(2):254-259.

Fehlmann D, Langenegger D, Schuepbach E, Siehler S, Feuerbach D, Hoyer D. 2000. Distribution and characterisation of somatostatin receptor mRNA and binding sites in the brain and periphery. *J Physiol Paris.* 94(3-4):265-281.

Fehmann HC, Habener JF. 1992. Insulinotropic hormone glucagon-like peptide-1- (7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma _TC-1 cells. *Endocrinology* 130:159–166.

Ferrer JC, Favre C, Gomis RR, Fernandez-Novell JM, Garcia-Rocha M, de I, I, Cid E, Guinovart JJ 2003. Control of glycogen deposition. *FEBS Lett.* 546(1):127-132.

Fishman. M. P., & Melton, D. A. 2002. Pancreatic lineage analysis using a retroviral vector in embryonic mice demonstrates a common progenitor for endocrine and exocrine cells. *The international Journal of Developmental Biology.* 46(2): 201-207.

Florio T., Yao H., Carey K.D., Dillon T.J., 1999. Somatostatin activation of mitogen-activated protein kinase via somatostatin receptor 1 (SSTR1). *Mol. Endocrinol.* 13(1): 24-37.

Fujii Y, Gono T, Yamada Y, Chihara K, Inagaki N, Seino S. 1994. Somatostatin receptor subtype SSTR2 mediates the inhibition of high-voltage-activated calcium channels by somatostatin and its analogue SMS 201-995. *FEBS Lett.* 355(2):117-120.

Funckes CL, Deschenes CD, Magazin R, et al. 1983. Cloning and characterization of mRNA-encoding at preprosomatostatin. *J Biol Chem.* 258(14):8781-8787.

Gerich JE 1998. The genetic basis of type 2 diabetes mellitus: impaired insulin secretion versus impaired insulin sensitivity. *Endocr Rev.* 19(4):491-503.

Gerich JE, Lorenzi M, Karam JH, Schneider V, Forsham PH. 1975. Abnormal pancreatic glucagon secretion and postprandial hyperglycemia in diabetes mellitus. *JAMA.* 234(2):159-165.

Gerich JE, Schultz TA, Lewis SB, Karam JH. 1977. Clinical evaluation of somatostatin as a potential adjunct to insulin in the management of diabetes mellitus. *Diabetologia*. 13(5):537-544.

Gerich JE. 1990. Role of somatostatin and its analogues in the pathogenesis and treatment of diabetes mellitus. *Metabolism*. 39(9 Suppl 2):52-54.

German M, Ashcroft S, Docherty K, et al. 1995. The insulin gene promoter. A simplified nomenclature. *Diabetes*. 44: 1002-1004.

Gonzalez GA, Montminy MR. 1989. Cyclic AMP stimulates somatostatin gene transcription by phosphorylation of CREB at serine 133. *Cell*. 59(4):675-680.

Gorden P, Comi RJ, Maton PN, Go VL. 1989. NIH conference. Somatostatin and somatostatin analogue (SMS 201-995) in treatment of hormone-secreting tumors of the pituitary and gastrointestinal tract and non-neoplastic diseases of the gut. *Ann Intern Med*. 110(1):35-50.

Grant MB, Mames RN, Fitzgerald C, Hazariwala KM, Cooper-DeHoff R, Caballero S, Estes KS. 2000. The efficacy of octreotide in the therapy of severe nonproliferative and early proliferative diabetic retinopathy: a randomized controlled study. *Diabetes Care*. 23(4):504-509.

Grossman LD, Shumak SL, George SR, Singer W, Zinman B. 1989. The effects of SMS 201-995 (sandostatin) on metabolic profiles in insulin-dependent diabetes mellitus. *J Clin Endocrinol Metab*. 68(1):63-67.

Gutniak M, Grill V, Wiechel KL, Efendic S. 1987. Basal and meal-induced somatostatin-like immunoreactivity in healthy subjects and in IDDM and totally pancreatectomized patients. Effects of acute blood glucose normalization. *Diabetes*. 36(7):802-807.

Habener JF, Kemp DM, Thomas MK. 2005 Minireview: transcriptional regulation in pancreatic development. *Endocrinology*. 146(3):1025-1034.

Halban PA, Powers SL, George KL, Bonner-Weir S. 1987. Spontaneous reassociation of dispersed adult rat pancreatic islet cells into aggregates with 3-dimensional architecture typical of native islets. *Diabetes*. 36(7): 783-791.

Hansen AP, Johansen K. 1970. Diurnal patterns of blood glucose, serum free fatty acids, insulin, glucagon and growth hormone in normals and juvenile diabetics. *Diabetologia*. 6(1):27-33.

Hanson RW, Reshef L. 1997. Regulation of phosphoenolpyruvate carboxykinase (GTP) gene expression. *Annu Rev Biochem*. 66:581-611.

Henquin JC 2000. Triggering and amplifying pathways of regulation of insulin secretion by glucose. *Diabetes*. 49(11):1751-1760.

Herzig S, Hedrick S, Morante I, Koo SH, Galimi F, Montminy M 2003. CREB controls hepatic lipid metabolism through nuclear hormone receptor PPAR-gamma. *Nature*. 426 (6963):190-193.

Hippen AR, She P, Young JW, Beitz DC, Lindberg GL, Richardson LF, Tucker RW 1999. Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. *J Dairy Sci*. 82 (6):1139-1152.

Hocart, S. J., Jain, R., Murphy, W. A., Taylor, J. E., Morgan, B. & Coy, D. H. 1998. Potent antagonist of somatostatin: synthesis and biology. *J. Med. Chem.* 41(7):1146-1154.

Hoyer D, Nunn C, Hannon J, Schoeffter P, Feuerbach D, Schuepbach E, Langenegger D, Bouhelal R, Hurth K, Neumann P, Troxler T, Pfaeffli P. 2004. SRA880, in vitro

characterization of the first non-peptide somatostatin sst(1) receptor antagonist. *Neurosci Lett.* 361(1-3):132-135.

Hunyady B, Hipkin RW, Schonbrunn A, Mezey E 1997. Immunohistochemical localization of somatostatin receptor SST2A in the rat pancreas. *Endocrinology.* 138(7):2632–2635.

Ishihara H, Maechler P, Gjinovci A, Herrera PL, Wollheim CB. 2003. Islet beta-cell secretion determines glucagon release from neighbouring alpha-cells. *Nat Cell Biol.* 5(4):330-335.

Janecka A, Zubrzycka M, Janecki T. 2001. Somatostatin analogs. *J Pept Res.* 58(2):91-107.

Kaiser N, Leibowitz G, Nesher R. 2003. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. *J. Pediatr Endocrinol Metab.* 16(1): 5-22.

Kemp DM, Habener JF. 2002. Synergistic effect of dimethyl sulfoxide on glucagon-like peptide 1 (GLP-1)-stimulated insulin secretion and gene transcription in INS-1 cells: characterization and implications. *Biochem Pharmacol.* 64(4):689-697

Kohner EM. 1993. Diabetic retinopathy. *BMJ* 307(6913):1195-1199.

Krulich L, Dhariwal AP, McCann SM. 1968. Stimulatory and inhibitory effects of purified hypothalamic extracts on growth hormone release from rat pituitary in vitro. *Endocrinology.* 83 (4): 783-790.

Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC, Patel YC 1999. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. *Diabetes.* 48(1):77-85.

Lahlou M, Guillermet J, Hortala M, Vernejoul F, Pyronnet S, Bousquet C, Susini C. 2004. Molecular signalling of somatostatin receptors. *Ann N Y Acad Sci.* 1014: 121-131.

Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. 1996. *N Engl J Med.* 334(4):246-254.

Lamberts SW, van der Lely AJ, Hofland LJ. 2002. New somatostatin analogs: will they fulfil old promises? *Eur J Endocrinol.* 146(5):701-705.

Lars Neisig Møller, Carsten Enggaard Stidsen, Bolette Hartmann and Jens Juul Holst. 2003. Somatostatin receptors. *Biochim Biophys Acta.* 1616(1):1-84.

Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, Demarest KT 2004. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. *Diabetes.* 53(2):410-417.

Lins PE, Efendic S, Meyers CA, Coy DH, Schally A, Luft R. 1980. Selective effect of some somatostatin analogs on glucagon as opposed to insulin release in rats in vivo. *Metabolism.* 29(8):728-731.

Ludvigsen E, Olsson R, Stridsberg M, Janson ET, Sandler S 2004. Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats. *J Histochem Cytochem.* 52(3):391-400.

Luft R, Cerasi E. 1964. Effect of human growth hormone on insulin production in panhypopituitarism. *Lancet.* 2:124-126.

Magnusson I, Rothman DL, Gerard DP, Katz LD, Shulman GI 1995. Contribution of hepatic glycogenolysis to glucose production in humans in response to a physiological increase in plasma glucagon concentration. *Diabetes.* 44(2):185-189.

Mitra SW, Mezey E, Hunyady B, Chamberlain L, Hayes E, Foor F, Wang Y, Schonbrunn A, Schaeffer JM. 1999. Colocalization of somatostatin receptor sst5 and insulin in rat pancreatic beta-cells. *Endocrinology*. 140(8):3790-3796.

Moldovan S, Atiya A, Adrian TE, Kleinman RM, Lloyd K, Olthoff K, Imagawa D, Shevlin L, Coy D, Walsh J 1995. Somatostatin inhibits B-cell secretion via a subtype-2 somatostatin receptor in the isolated perfused human pancreas. *J Surg Res*. 59(1):85–90.

Montminy M, Goodman R, Horovitch S, et al. 1984 Primary structure of the gene encoding rat preprosomatostatin. *Proc Natl Acad Sci. USA*.81(11):3337-3340.

Murphy WA, Lance VA, Moreau S, Moreau JP, Coy DH. 1987. Inhibition of rat prostate tumor growth by an octapeptide analog of somatostatin. *Life Sci*. 40(26):2515-2522.

Noe BD, Milgram SL, Balasubramaniam A, Andrews PC, Calka J, McDonald JK. 1989. Localization and characterization of neuropeptide Y-like peptides in the brain and islet organ of the anglerfish (*Lophius americanus*). *Cell Tissue Res*. 257(2):303-311.

Ohlsson H, Karlsson K & Edlund T. 1993. IPFI a homeodomain containing transactivator of the insulin gene. *EMBO Journal*. 12(11): 4251-4259.

Ohneda A, Watanabe K, Horigome K, Sakai T, Kai Y, Oikawa S 1978. Abnormal response of pancreatic glucagon to glycemic changes in diabetes mellitus. *J.Clin.Endocrinol.Metab* 46(3): 504-510.

Orci L, Unger RH. 1975. Functional subdivision of islets of Langerhans and possible role of D cells. *Lancet*. 2(7947):1243-1244.

Patel Y, Amherdt M, Orci L. 1982. Quantitative electron microscopic autoradiography of insulin, glucagon and somatostatin binding sites on islets. *Science*. 217(4565):1155-1156.

Patel YC, Greenwood M, Panetta R, Hukovic N, Grigorakis S, Robertson LA, Srikant CB. 1996. Molecular biology of somatostatin receptor subtypes. *Metabolism*. 45 (8 Suppl 1):31-38.

Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. 1995. The somatostatin receptor family. *Life Sci*. 57(13):1249-1265.

Patel YC, Srikant CB. 1994. Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). *Endocrinology*. 135(6):2814-2817.

Patel YC, Weir GC. 1976. Increased somatostatin content of islets from streptozotocin-diabetic rats. *Clin Endocrinol (Oxf)*. 5(2):191-194.

Patel YC. 1999 Somatostatin and its receptor family. *Front Neuroendocrinol*. 20(3):157-198.

Pipeleers DG, Schuit FC, Van Schravendijk CF, Van de Winkel M. 1985. Interplay of nutrients and hormones in the regulation of glucagon release. *Endocrinology*. 117(3):817-823.

Plewe G, Beyer J, Krause U, Neufeld M, del Pozo E. 1984. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. *Lancet*. 2(8406):782-784.

Poitout L, Roubert P, Contour-Galcera MO, Moinet C, Lannoy J, Pommier J, Plas P, Bigg D, Thuriel C. 2001. Identification of potent non-peptide somatostatin antagonists with sst(3) selectivity. *J Med Chem*. 44(18):2990-3000.

Polonsky KS, Jaspan JB, Berelowitz M, Emmanouel DS, Dhorajiwala J. 1981. Hepatic and renal metabolism of somatostatin-like immunoreactivity. Simultaneous assessment in the dog. *J Clin Invest*. 68(5):1149-1157.

Portela-Gomes GM, Stridsberg M, Grimelius L, Oberg K, Janson ET. 2000. Expression of the five different somatostatin receptor subtypes in endocrine cells of the pancreas. *Appl Immunohistochem Mol Morphol.* 8(2):126-132.

Postic C, Dentin R, Girard J 2004. Role of the liver in the control of carbohydrate and lipid homeostasis. *Diabetes Metab.* 30(5):398-408.

Raskin, P., Aydin, I., and Unger, R. H., 1976. The effect of the insulin on the exaggerated glucagon response to arginine stimulation in diabetes mellitus. *Diabetes.* 25(3): 227-229.

Raulf F, Perez J, Hoyer D, Bruns C. 1994. Differential expression of five somatostatin receptor subtypes, SSTR1-5, in the CNS and peripheral tissue. *Digestion* 55 Suppl 3:46-53.

Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW.1997. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: co expression with catalytically inactive SHP-2 blocks responsiveness. *Mol Endocrinol.* 11(8):1062-1069.

Reichlin S. Somatostatin. 1983. *N. Engl. J. Med.* 309(24):1495-1501.

Reubi J. C., Eisenwiener K. P., Rink H., Waser B. and Macke H. R. 2002. A new peptidic somatostatin agonist with high affinity to all five somatostatin receptors. *Eur. J. Pharmacol.* 456(1-3): 45–49.

Reubi J. C., Schaer J. C., Wenger S., Hoeger C., Erchegyi J., Waser B. and Rivier J. 2000. SST3-selective potent peptidic somatostatin receptor antagonists. *Proc. Natl. Acad. Sci. USA* 97(25):13973–13978.

Reubi JC, Kappeler A, Waser B, Schonbrunn A, Laissue J 1998. Immunohistochemical localization of somatostatin receptor sst2A in human pancreatic islets. *J Clin Endocrinol Metab* 83(10):3746-3749.

Ritz-Laser B, Estreicher A, Gauthier BR, Mamin A, Edlund H, Philippe J. 2002. The pancreatic beta-cell-specific transcription factor Pax-4 inhibits glucagon gene expression through Pax-6. *Diabetologia*. 45(1):97-107.

Rivier J, Brazeau P, Vale W, Guillemin R. 1975. Somatostatin analogs. Relative importance of the disulfide bridge and of the Ala-Gly side chain for biological activity. *J Med Chem*. 18(2):123-126.

Rizza, R.A., Mandarino, L.J., and Gerich, J.E. 1982. Effects of growth hormone on insulin action in man. Mechanisms of insulin resistance, impaired suppression of glucose production, and impaired stimulation of glucose utilization. *Diabetes*. 31(8Pt 1):663-669.

Robertson RP, Harmon J, Tran PO, Pointout V. 2004. Beta-cell glucose toxicity, lipotoxicity and chronic oxidative stress in type 2 diabetes. *Diabetes*. 53 (Suppl. 1): S119-124.

Rognstad R. 1979. Rate-limiting steps in metabolic pathways. *J Biol Chem*. 254(6):1875-1878.

Rohit N. Kulkarni. 2004. The islet β -cell. *Int J Biochem Cell Biol*. 36 (3):365–371.

Rohrer SP, Birzin ET, Mosley RT, Berk SC, Hutchins SM, Shen DM, Xiong Y, Hayes EC, Parmar RM, Foor F, Mitra SW, Degrado SJ, Shu M, Klopp JM, Cai SJ, Blake A, Chan WW, Pasternak A, Yang L, Patchett AA, Smith RG, Chapman KT, Schaeffer JM. 1998. Rapid identification of subtype-selective agonists of the somatostatin receptor through combinatorial chemistry. *Science*. 282(5389):737-740.

Rohrer SP, Schaeffer JM. 2000. Identification and characterization of subtype selective somatostatin receptor agonists. *J Physiol Paris*. 94(3-4):211-215.

Rossowski WJ, Coy DH. 1994. Specific inhibition of rat pancreatic insulin or glucagon release by receptor-selective somatostatin analogs. *Biochem Biophys Res Commun*. 205(1): 341-346.

Saltiel AR, Kahn CR. 2001. Insulin signalling and the regulation of glucose and lipid metabolism. *Nature*. 414(6865):799-806.

Samols E, Bonner-Weir S, Weir GC. 1986. Intra-islet insulin-glucagon-somatostatin relationships. *Clin Endocrinol Metab*. 15(1):33-58.

Samols E, Stagner J. 1990. Islet somatostatin-microvascular, pancreatic and pulsatile regulation. *Metabolism*. 39(9 Suppl 2): 55-60.

Samols E., and Harrison, J. 1976. Intra-islet negative insulin/glucagon feedback. *Metabolism* 25(Suppl.): 1443-1447.

Samols E., Marri, G., and Marks, V. 1965. Promotion of insulin secretion by glucagon. *Lancet* 2: 415-416.

Sander M, German M. 1997. The beta cell transcription factors and development of the pancreas. *J Mol Med*. 75(5):327-340.

Sander M, Neubuser A, Kalamaras J, Ee HC, Martin GR, German MS. 1997. Genetic analysis reveals that PAX6 is required for normal transcription of pancreatic hormone genes and islet development. *Genes Dev*. 11(13):1662-1673.

Segers O, De Vroede M, Michotte Y, Somers G. 1989. Basal and tolbutamide-induced plasma somatostatin in healthy subjects and in patients with diabetes and impaired glucose tolerance. *Diabet Med.* 6(3):232-238.

Shah P, Basu A, Basu R, Rizza R 1999. Impact of lack of suppression of glucagon on glucose tolerance in humans. *Am.J.Physiol* 277(2 Pt 1):E283-E290.

Shimano H, Horton JD, Hammer RE, Shimomura I, Brown MS, Goldstein JL 1996. Overproduction of cholesterol and fatty acids causes massive liver enlargement in transgenic mice expressing truncated SREBP-1a. *J Clin Invest.* 98(7):1575-1584.

Shimon I., Yan X., Taylor J. E., Weiss M. H., Culler M. D. and Melmed S. 1997. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. *J. Clin. Invest.* 100(9): 2386–2392.

Singh V, Brendel MD, Zacharias S, Mergler S, Jahr H, Wiedenmann B, Bretzel RG, Plockinger U, Strowski MZ. 2007. Characterization of somatostatin receptor subtype-specific regulation of insulin and glucagon secretion: an in vitro study on isolated human pancreatic islets. *J Clin Endocrinol Metab.* 92(2):673-680.

Skoglund G, Hussain MA, Holz GG. 2000. Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element. *Diabetes.* 49(7):1156-1164.

Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D, Foley E, Smith RG, Schaeffer JM. 1997. Essential Role of Growth Hormone in Ischemia-Induced Retinal Neovascularization. *Science.* 276(5319):1706-1709.

Sosa-Pineda B, Chowdhury K, Torres M, Oliver G, Gruss P. 1997. The Pax4 gene is essential for differentiation of insulin-producing beta cells in the mammalian pancreas. *Nature*. 386(6623):399-402.

St-Onge L, Sosa-Pineda B, Chowdhury K, Mansouri A, Gruss P. 1997. Pax6 is required for differentiation of glucagon-producing alpha-cells in mouse pancreas. *Nature*. 387(6631):406-409.

Strowski MZ, Cashen DE, Birzin ET, Yang L, Singh V, Jacks TM, Nowak KW, Rohrer SP, Patchett AA, Smith RG, Schaeffer JM. 2006. Antidiabetic activity of a highly potent and selective nonpeptide somatostatin receptor subtype-2 agonist. *Endocrinology*. 147(10):4664-4673.

Strowski MZ, Kohler M, Chen HY, Trumbauer ME, Li Z, Szalkowski D, Gopal-Truter S, Fisher JK, Schaeffer JM, Blake AD, Zhang BB, Wilkinson HA. 2003. Somatostatin receptor subtype 5 regulates insulin secretion and glucose homeostasis. *Mol Endocrinol*. 17(1):93-106.

Strowski MZ, Parmar RM, Blake AD, Schaeffer JM 2000. Somatostatin inhibits insulin and glucagon secretion via two receptors subtypes: an in vitro study of pancreatic islets from somatostatin receptor 2 knockout mice. *Endocrinology*. 141(1):111-117.

Tulipano G., Soldi D., Bagnasco M., Culler M. D., Taylor J. E., Cocchi D. and Giustina A. 2002. Characterization of new selective somatostatin receptor subtype-2 (sst2) antagonists, BIM-23627 and BIM-23454. Effects of BIM-23627 on GH release in anesthetized male rats after short-term high-dose dexamethasone treatment. *Endocrinology* 143(4): 1218–1224.

Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM. 1970. Studies of pancreatic alpha cell function in normal and diabetic subjects. *J. Clin. Invest.* 49(4): 837-848.

Unger RH, Ipp E, Schusdziarra V, Orci L. 1977. Hypothesis: physiologic role of pancreatic somatostatin and the contribution of D-cell disorders to diabetes mellitus. *Life Sci.* 20(12):2081-2085.

Unger RH, Orci L. 1977. Possible roles of the pancreatic D-cell in the normal and diabetic states. *Diabetes.* 26(3):241-244.

Unger RH. 1995. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Genetic and clinical implications. *Diabetes.* 44(8): 863-870.

Van Liessum PA, Hopman WP, Pieters GF, Jansen JB, Smals AG, Rosenbusch G, Kloppenborg PW, Lamers CB. 1989. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. *J Clin Endocrinol Metab.* 69(3):557-562.

Van Steenbergen W, Lanckmans S 1995. Liver disturbances in obesity and diabetes mellitus. *Int J Obes Relat Metab Disord.* 19 Suppl 3:S27-S36.

Villar-Palasi C, Guinovart JJ 1997. The role of glucose 6-phosphate in the control of glycogen synthase. *FASEB J* 11(7):544-558.

Waeber G, Thompson N, Nicod P, Bonny C. 1996. Transcriptional activation of the GLUT2 gene by the IPF-1/STF-1/IDX-1 homeobox factor. *Mol Endocrinol.* 10(11):1327-1334.

Watada H, Kajimoto Y, Umayahara Y, Matsuoka T, Kaneto H, Fujitani Y, Kamada T, Kawamori R, Yamasaki Y. 1996. The human glucokinase gene beta-cell-type promoter: an essential role of insulin promoter factor 1/PDX-1 in its activation in HIT-T15 cells. *Diabetes.* 45(11):1478-1488.

Weckbecker G, Lewis I, Albert R, Schmid HA, Hoyer D, Bruns C. 2003. Opportunities in somatostatin research: biological, chemical and therapeutic aspects. *Nat Rev Drug Discov.* (12):999-1017.

Wilkinson G. F., Thurlow R. J., Sellers L. A., Coote J. E., Feniuk W. and Humphrey P. P. 1996. Potent antagonism by BIM-23056 at the human recombinant somatostatin sst5 receptor. *Br. J. Pharmacol.* 118(3): 445–447.

Williams G, Fuessl HS, Burrin JM, Chilvers E, Bloom SR. 1988. Postprandial glycaemic effects of a long-acting somatostatin analogue (octreotide) in non-insulin dependent diabetes mellitus. *Horm Metab Res.* 20(3):168-170.

Winder WW, Hardie DG. 1999. AMP-activated protein kinase, a metabolic master switch: possible roles in type 2 diabetes. *Am J Physiol.* 277(1 Pt 1):E1-10.

Yamada Y, Post SR, Wang K, Tager HS, Bell GI, Seino S. 1992. Cloning and functional characterization of a family of human and mouse somatostatin receptors expressed in brain, gastrointestinal tract, and kidney. *Proc Natl Acad Sci U S A.* 89(1): 251–255.

Yamada Y, Reisine T, Law SF, Ihara Y, Kubota A, Kagimoto S, Seino M, Seino Y, Bell GI, Seino S. 1992. Somatostatin receptors, an expanding gene family: cloning and functional characterization of human SSTR3, a protein coupled to adenylyl cyclase. *Mol. Endocrinol.* 6(12): 2136-2142.

Yamada Y., Kagimoto S., Kubota A., Yasuda K., Masuda K., Someya Y., Ihara Y., Li Q., Imura H., Seino S. and Seino Y. 1993. Cloning, Functional Expression and Pharmacological Characterization of a Fourth (hSSTR4) and a Fifth (hSSTR5) Human Somatostatin Receptor Subtype. *Biochem. Biophys. Res. Commun.* 195(2): 844-852.

Zambre Y, Ling Z, Chen MC, Hou X, Woon CW, Culler M, Taylor JE, Coy DH, Van Schravendijk C, Schuit F, Pipeleers DG, Eizirik DL 1999. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. *Biochem Pharmacol* 57(10): 1159–1164.